Researchers in Israel this week announced that Pfizer-BioNTech’s Covid-19 vaccine has appeared to reduce symptomatic coronavirus infections by more than 90% in the real world now that more and more populations are receiving their doses.
The preliminary findings suggest that the vaccine itself has remained as successful as researchers initially proved in their vaccine trials. Within a clinical vaccine trial the conditions are greatly controlled to monitor the actual effectiveness of the shot, however, that monitoring already eliminates a slew of other risks that exist within the real world that could impact the vaccine’s efficacy.
Luckily, nothing of the sort has occurred, and the vaccine is still wildly successful. The Clalit Research Institute is a major part of Israel’s healthcare system, and they’re the ones who analyzed data on 1.2 million individuals; half of which received the Pfizer-BioNTech vaccine. The researchers wanted to compare patients who had received the vaccine and individuals with similar immune systems who hadn’t.
The researchers wanted to analyze the rate in which symptomatic Covid-19 was spreading with the release of this vaccine; meaning they looked at individuals who contracted the virus and actually felt sick. Symptomatic Covid-19 was proven to decrease by 94% among individuals who have received their two doses of the vaccine, according to a press release from Clalit. The rate of serious illness caused by the virus decreased by 92%.
The research has yet to be published by the Institute because they’re still waiting for it to be peer-reviewed so that the results are as accurate as possible. However, the results are already consistent with the data that Pfizer initially released to prove their vaccine would be effective.
Pfizer’s initial data from their vaccine trial showed that their Covid-19 vaccine was 95% effective against symptomatic coronavirus. In the trial itself, participants were either given the actual vaccine or a placebo. They then observed how many people from each group got infected after the fact.
Pfizer’s clinical study was considered to be the “golden standard in clinical research” according to the Institute due to the fact that it was a randomized and controlled trial. The studies from Israel are now observational, meaning researchers aren’t randomly picking individuals who got the vaccine or not already.
Observational studies can skew the data in this case, however, due to the fact that different individuals who choose to be vaccinated are likely going to take less or more steps towards protecting themselves from potential infection.
While the observational aspect of this study may not be as effective as a controlled trial, the combination of these new results with the results that came from Pfizer and BioNTech themselves shows the world that the vaccine is just as effective as anticipated, and we should all continue to do our parts to protect each other and bring this pandemic to an end.
Eric Mastrota is a Contributing Editor at The National Digest based in New York. A graduate of SUNY New Paltz, he reports on world news, culture, and lifestyle. You can reach him at firstname.lastname@example.org.